Table 7.

Signs and symptoms associated with injection site reactions in the OLE by previous randomization (safety-evaluable population)

	Participants previously on placebo (n = 117)	Participants previously on gantenerumab (n = 108)	Total (N = 225)
Total number of participants with at least one sign or symptom associated with administration-related reactions, n (%)	48 (41.0)	44 (40.7)	92 (40.9)
Overall total number of events reported as a sign or symptom associated with administration-related reactions, n	377	395	772
General disorders and administration site conditions
Injection site erythema, n (%)	41 (35.0)	32 (29.6)	73 (32.4)
Injection site pruritus, n (%)	10 (8.5)	12 (11.1)	22 (9.8)
Injection site swelling, n (%)	11 (9.4)	6 (5.6)	17 (7.6)
Injection site induration, n (%)	9 (7.7)	3 (2.8)	12 (5.3)
Injection site rash, n (%)	3 (2.6)	5 (4.6)	8 (3.6)
Injection site pain, n (%)	4 (3.4)	3 (2.8)	7 (3.1)
Injection site bruising, n (%)	1 (0.9)	1 (0.9)	2 (0.9)
Injection site dermatitis, n (%)	1 (0.9)	1 (0.9)	2 (0.9)
Injection site discoloration, n (%)	1 (0.9)	1 (0.9)	2 (0.9)
Injection site hematoma, n (%)	1 (0.9)	1 (0.9)	2 (0.9)
Injection site inflammation, n (%)	2 (1.7)	0	2 (0.9)
Injection site edema, n (%)	1 (0.9)	1 (0.9)	2 (0.9)
Injection site urticaria, n (%)	1 (0.9)	1 (0.9)	1 (0.4)
Injection site warmth, n (%)	2 (1.7)	0	1 (0.4)
Infusion site inflammation, n (%)	1 (0.9)	0	1 (0.4)
Infusion site pain, n (%)	0	1 (0.9)	1 (0.4)
Injection site hemorrhage, n (%)	1 (0.9)	0	1 (0.4)
Injection site irritation, n (%)	1 (0.9)	0	1 (0.4)
Injection site macule, n (%)	0	1 (0.9)	1 (0.4)
Injection site reaction, n (%)	0	1 (0.9)	1 (0.4)
Skin and subcutaneous tissue disorders
Pruritus, n (%)	1 (0.9)	0	1 (0.4)
Rash erythematous, n (%)	1 (0.9)	0	1 (0.4)

OLE, open-label extension.